| Lumigan (U.S.N.L.M.) | ||
|---|---|---|
| Dosing | 1 drop qPM (optimal), (qAM dosing is considered acceptable.) | |
| Chem Specs | bimatoprost 0.01%, 0.03% | |
| Quantities | 2.5, 5, 7.5ml | |
| Cost | 131.48/2.5ml | |
| Class | prostaglandin analog | |
| Action | Increased uveoscleral aqueous outflow by loosening intercellular spaces on the ciliary body face. 28% - 30% IOP reduction. Increased uveoscleral aqueous outflow by loosening intercellular spaces on the ciliary body face. 28% - 30% IOP reduction. |
|
| Usage | Indicated for the reduction of elevated IOP in open angle glaucoma or ocular hypertension. Indicated for the reduction of elevated IOP in open angle glaucoma or ocular hypertension. |
|
| Side Effects | Lid, lash, and iris pigmentation. Eyelash growth. Small risk of CME and uveitis in pseudophakes and/or aphakes. Possible reactivation of herpes keratitis. 25% – 45% conjunctival hyperemia . Lid, lash, and iris pigmentation. Eyelash growth. Small risk of CME and uveitis in pseudophakes and/or aphakes. Possible reactivation of herpes keratitis. 25% – 45% conjunctival hyperemia . |
|
| Contraindications | Hypersensitivity to bimatoprost or any of its ingredients. | |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. | |
| Pregnancy | Category C. Increased fetal mortality observed in rats at 41 times but not at 14 times the normal human dose. Category C. Increased fetal mortality observed in rats at 41 times but not at 14 times the normal human dose. |
|
| Combined use with pilocarpine is not recommended. | ||
| BAK preserved. (0.2mg/ml BAK in the 0.01% formulation. 0.3mg/ml BAK in the 0.03%). Generic (Lupin Pharmaceuticals), 0.03% with 0.005% BAK. BAK preserved. (0.2mg/ml BAK in the 0.01% formulation. 0.3mg/ml BAK in the 0.03%). Generic (Lupin Pharmaceuticals), 0.03% with 0.005% BAK. |
||